Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa.

Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM, MORDOR Study Group. · 2018

Read Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. by Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM, MORDOR Study Group. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5849140.txt.

Introduction

Keenan and co-authors report the MORDOR trial, which tested mass azithromycin against child deaths in Africa. Their report appeared in The New England Journal of Medicine. Communities in Malawi, Niger, and Tanzania were randomized by village. Preschool children got the antibiotic or a placebo twice a year.

Over 190,000 children were followed across 1,533 communities. Deaths ran about 14 percent lower where azithromycin was given. The gain centered on Niger and on the youngest infants. Among babies one to five months old, deaths fell by roughly a quarter. The authors warn that resistance could follow wide use.

Catalog record

CREATORKeenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM, MORDOR Study Group.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5849140

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa By Jeremy D Keenan, Robin L Bailey, Sheila K West, Ahmed M Arzika, John Hart, Jerusha Weaver, Khumbo Kalua, Zakayo Mrango, Kathryn J Ray, Catherine Cook, Elodie Lebas, Kieran S O'Brien Published in: The New England Journal of Medicine DOI: 10.1056/NEJMoa1715474 ABSTRACT Background. Interventions to reduce under-5 mortality can either target the vulnerable or include all children regardless of state of health. Here, we assess whether mass distribution of a broad-spectrum antibiotic to pre-school children reduces mortality in sub-Saharan Africa. Methods. MORDOR was a large simple trial that randomized communities in Malawi, Niger, and Tanzania to 4 biannual mass distributions of either oral azithromycin or placebo. Children aged 1-59 months were enumerated and offered treatment. Vital status was assessed at the subsequent biannual census. The primary outcome was aggregate all-cause mortality, with country-specific rates as pre-specified subgroup analyses. Results. In total, 1533 communities were randomized, 190,238 children censused at baseline, and 323,302 person-years monitored. Mean antibiotic coverage over the 4 biannual distributions was 90.4% (SD 10.4%) of the censused population. The overall annual mortality rate in placebo- treated communities was 16.5 per 1000 person-years (9.6 per 1000 person-years in Malawi, 27.5 in Niger, and 5.5 in Tanzania). Antibiotic-treated communities had an estimated 13.5% lower mortality overall (95% CI 6.7%—19.8%, P<0.001). Mortality was 5.7% lower in Malawi (CI - 9.7%—18.9%, P=0.45), 18.1% lower in Niger (CI 10.0%—25.5%, P<0.001), and 3.4% lower in Tanzania (CI -21.2%—23.0%, P=0.77). The greatest reduction was observed in 1-5 month-old children (24.9% lower, CI 10.6%—37.0%, P=0.001). Conclusions. Mass azithromycin distribution to post-neonatal, pre-school children may reduce childhood mortality in sub-Saharan Africa, particularly in high mortality areas such as Niger. Any implementation would need to consider selection for antibiotic resistance. INTRODUCTION Trachoma control programs have distributed more than 600 million doses of oral azithromycin in an effort to eliminate the ocular strains of chlamydia that cause the disease.12 Azithromycin has been effective against trachoma, although distributions have caused gastrointestinal side effects and selected for macrolide-resistant strains of Streptococcus pneumoniae and Escherichia coli.3-8 Investigators have also noted possible benefits against a number of infectious diseases including malaria, diarrhea, and pneumonia.9-14 A case-control study and community-randomized trial in a trachoma-endemic area of Ethiopia suggested that mass azithromycin may even reduce childhood mortality.15,16 Experts believed a mortality benefit possible, although likely smaller in magnitude than found in these studies.17 Here, we tested the hypothesis that biannual mass distributions of oral azithromycin can reduce mortality in children aged 1-59 months. The study was performed in 3 geographically distinct areas: Malawi in Southern Africa, Niger in West Africa, and Tanzania in East Africa. Azithromycin affects transmissible diseases, so treating one individual might influence others in the same community. Thus randomization and intervention were at the community level, and inferences of efficacy were made at the community level. As mortality is a relatively rare event even in these settings, a large study population was required. Hence we adopted a large simple trial paradigm with a straightforward intervention and primary outcome.18 METHODS Eligibility MORDOR (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) was a community-randomized trial conducted in the Malawian district of Mangochi, the Nigerien districts of Boboye and Loga, and the Tanzanian districts of Kilosa and Gairo. The randomization unit was a health surveillance assistant area in Malawi, a grappe in Niger, and a hamlet in Tanzania. Communities with a population between 200 and 2000 inhabitants on the most recent census were eligible for enrollment (Supplementary Appendix). Enrollment was based on census information available prior to the study. Communities remained in the study even if the population drifted out of this range. All children aged 1-59 months (truncated to month) weighing at least 3,800 grams were eligible for treatment. Randomization and masking Lists of communities from the most recent pre-trial census were submitted to the UCSF data coordinating center. For each country, communities were randomly assigned in equal proportions to 1 of 10 letters, with 5 letters coded for azithromycin and 5 for placebo (Statistical Analysis Plan, SAP). Randomization was generated in R (R Foundation for Statistical Computing, Vienna, Austria) using the sample command (TCP), with knowledge of the link between treatment letter and arm assignment limited (TCP, KJR, and personnel necessary for labeling and packaging). Centralized randomization and simultaneous assignment of communities facilitated complete allocation concealment. Participants, observers, investigators, and data-cleaning team members were masked to treatment arm. The placebo contained the vehicle of the oral azithromycin suspension and was identical in appearance with identical bottles and labels. Census A house-to-house census was performed during 5 prescribed 6-month periods, allowing a 2-month grace period for the initial census. At the initial census, all households in the community were entered into a custom-built mobile application (Conexus Inc., Los Gatos, CA), with the head of household name and GPS coordinates used to facilitate locating the household at the subsequent census. All children in the household aged 1-59 months were enumerated. Pregnant women and children under 1 month were also documented in anticipation of the following census. At follow-up censuses, the vital status (alive, dead, or unknown) and residence (living in community, moved outside community, or unknown) were recorded for children present in census records. New 0-59 month-old children and pregnant women were also entered. Communities were censused in the same general order throughout the study. Data were uploaded to the Salesforce Cloud Database Service (Salesforce.com, San Francisco, CA). Data cleaning was performed using Salesforce.com, Stata (Statacorp, College Station, TX), and R. Intervention Each child aged 1-59 months at the census was offered a single, directly observed dose of oral azithromycin or placebo (both provided by Pfizer, Inc., New York, NY). A volume of suspension corresponding to at least 20 mg/kg was given by height-stick approximation according to the country’s trachoma program guidelines, or by weight for those unable to stand. Children known to be allergic to macrolides were not treated. Treatments were administered at the census and during additional visits in an attempt to achieve at least 80% coverage. Administration of study medication was documented for each child in the mobile application, and community coverage was calculated relative to the census. Guardians were instructed to contact a village representative for any adverse events noted after taking the study medication. This individual reported to the site study coordinator, who in turn reported to the Data Coordinating Center at UCSF. Primary outcome The pre-specified primary outcome was the community-level, aggregate, 3- country mortality rate determined by biannual census. Each inter-census period was treated separately, with a mortality event counted only when a child was recorded as being alive and living in the household at the initial census, and recorded as having died while residing in the community at the subsequent census. By design, no attempt was made to track down a child’s status after movement outside the community. Person-time at risk was calculated as days between consecutive censuses, with children who moved, died, or had an unknown follow-up status contributing one half the inter-census period. All children documented as alive and living in the household at the initial census of each inter-census period were included in the analysis. No changes to trial outcomes

Read the complete text